review · Annals of Medicine and Surgery

The safety and efficacy of Baricitinib for systemic lupus erythematosus: a systematic review and meta-analysis of randomized controlled trials

Alaa Ramadan
Othman Saleh
Mohammad A. Elzeftawy
Mohamed Abuelazm
Nathan Ezie Kengo
Unaiza Ahmad
Ibrahim Gowaily
Basel Abdelazeem

20241 citationOpen accessSouth Valley University

Abstract

Baricitinib is associated with significant outcomes of SRI-4 response, greater than or equal to 4-point improvement SLEDAI-2K score, and Joint Indices. Regarding safety, there was no difference in the outcomes other than the serious adverse events.

Research topics

Systemic Lupus Erythematosus Research
Atherosclerosis and Cardiovascular Diseases
Cytokine Signaling Pathways and Interactions

Sustainable Development Goals

Good Health and Well-being

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

View on publisher site Record on OpenAlex

DOI: 10.1097/ms9.0000000000002548

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.

New to MARATTO™? Create a free account.